Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14957200 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4EHTTTTR | |
| SCHEMBL14957199 | 0.92 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EHTTTTR | |
| SCHEMBL3022578 | 0.84 | GAA (0.54) | ALDH1A1SMN1; SMN2HTTMAPTCYP1A2 | |
| SCHEMBL7462244 | 0.83 | KMT2A (0.49) | ALDH1A1SMN1; SMN2HTTMAPTRAB9A | |
| SCHEMBL7462254 | 0.83 | KMT2A (0.49) | ALDH1A1SMN1; SMN2HTTMAPTRAB9A | |
| SCHEMBL27717169 | 0.83 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EHTTTTR | |
| SCHEMBL6896026 | 0.81 | MAPT (0.47) | ALDH1A1SMN1; SMN2KDM4EHTTMAPT | |
| SCHEMBL6896022 | 0.81 | MAPT (0.47) | ALDH1A1SMN1; SMN2KDM4EHTTMAPT | |
| SCHEMBL1249807 | 0.80 | HTT (0.58) | ALDH1A1SMN1; SMN2HTTTTRMAPT | |
| SCHEMBL3036335 | 0.80 | MAPT (0.52) | ALDH1A1SMN1; SMN2HTTMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912767-B2 | Anthracycline prodrugs and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20180110756-A1 | ANTHRACYCLINE PRODRUGS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2018-04-26 | — | — | US | disclosed |
| WO-2016176332-A1 | ANTHRACYCLINE PRODRUGS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20130126860-A1 | THIN FILM TRANSISTOR SUBSTRATE | DAI NIPPON PRINTING CO., LTD. (JP) | 2013-05-23 | — | — | US | disclosed |
| CN-101137620-B | Alkali proliferating agent and alkali-reactive curable composition | SEKISUI CHEMICAL CO LTD | 2011-05-25 | — | — | CN | disclosed |
| US-7714162-B2 | Base multiplying agents and base-reactive curable compositions | SEKISUI CHEMICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20080200580-A1 | Base Multiplying Agents and Base-Reactive Curable Compositions | SEKISUI CHEMICAL CO., LTD (JP) | 2008-08-21 | — | — | US | disclosed |
| CN-101137620-A | Alkali proliferating agent and alkali-reactive curable composition | SEKISUI CHEMICAL CO LTD (JP) | 2008-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200580-A1 | Base Multiplying Agents and Base-Reactive Curable Compositions | RAD1, RAD51, REV1 | ALDH1A1 756/4885SMN1; SMN2 1784/4885KDM4E 3022/4885 |
| US-10912767-B2 | Anthracycline prodrugs and methods of making and using the same | TET3, DPYD, CYP2C9 | ALDH1A1 90/4885SMN1; SMN2 3669/4885KDM4E 59/4885 |
| US-20180110756-A1 | ANTHRACYCLINE PRODRUGS AND METHODS OF MAKING AND USING THE SAME | DPYD, TYMP, TOP1 | ALDH1A1 671/4885SMN1; SMN2 2484/4885KDM4E 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.